Squarepoint
BCAX

Squarepoint’s Bicara Therapeutics BCAX Stock Holding History

Squarepoint’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Buy
+10,771
New +$185K ﹤0.01% 3924
2025
Q3 		– Sell
-13,363
Closed -$124K – 5127
2025
Q2 		$124K Buy
+13,363
New +$159K ﹤0.01% 4112
2024
Q4 		– Sell
-44,774
Closed -$1.14M – 5586
2024
Q3 		$1.14M Buy
+44,774
New +$1.14M ﹤0.01% 2501

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Squarepoint's BCAX Position: Q1 2026 in Review

Squarepoint opened a new position in Bicara Therapeutics (BCAX) in Q1 2026: 10,771 shares worth $214K. The stake represents ﹤0.01% of the portfolio and ranks #3924 among its holdings. This is a return to the name: Squarepoint previously reported a position in BCAX as recently as Q2 2025.

Squarepoint first reported a position in BCAX in Q3 2024 and has held it in 3 quarters since. The position peaked at $1.14M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Squarepoint held 10,771 shares of Bicara Therapeutics worth $214K as of Q1 2026.
  • Bicara Therapeutics was a new Squarepoint position in Q1 2026.
  • Bicara Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3924 holding.
  • Squarepoint first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Squarepoint's Bicara Therapeutics position peaked at $1.14M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.